Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)
NCT06839235 · View on ClinicalTrials.gov ↗
Study Summary
The goal of the redePHine study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ABO-101 in participants with primary hyperoxaluria type 1 (PH1). The trial will consist of 2 Study Periods. During the first Study Period, there will be 2 parts. In Part A, adult participants will be treated with a single ascending dose to identify a recommended dose. In Part B, pediatric participants will be treated with the recommended dose. Following the first Study Period, participants will start Study Period 2, a long-term monitoring program to comply with local and national requirements.
Conditions Studied
Interventions
- DRUG ABO-101
Study Locations (7)
Other
- Hospices Civils de Lyon- Hôpital Femmes Mères Enfants — Lyon
- Kindernierenzentrum Bonn — Bonn
- Heidi Chaker — Sfax
- Queen Elizabeth Hospital Birmingham — Birmingham
- Royal Free Hospital — London
Minnesota
- Mayo Clinic — Rochester
- Nucleus Network — Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2025-06-16 |
| Est. Completion | 2043-02 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06839235
The ClinicalTrials.gov registry entry for NCT06839235 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arbor Biotechnologies, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Primary Hyperoxaluria Type 1 (PH1) appearing as the primary indexed condition, and to 1 intervention — of which ABO-101 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06839235 reports 7 study locations spanning 2 distinct geographic areas — top geographies include Other, Minnesota. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06839235 about?
NCT06839235 is a clinical study titled "Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)". The goal of the redePHine study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ABO-101 in participants with primary hyperoxaluria type 1 (PH1). The trial will consist of 2 Study Periods. During the first Study Period, there will be 2 parts. In Part A, adult partic...
What is the current status of trial NCT06839235?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2025-06-16. Estimated completion is 2043-02.
What conditions does trial NCT06839235 study?
This clinical trial studies the following conditions: Primary Hyperoxaluria Type 1 (PH1). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06839235?
The interventions under investigation include: ABO-101 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06839235?
This trial is sponsored by Arbor Biotechnologies, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06839235 being conducted?
This trial has 7 study locations across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.